First-line obinutuzumab for follicular lymphoma

被引：0
|
作者：
Baker, Holly
机构：
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 11期
关键词：
D O I：
10.1016/S1470-2045(17)30781-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E648 / E648
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong, Xiaonan
    Song, Yuqin
    Shi, Yuankai
    Zhang, Qingyuan
    Guo, Wei
    Wu, Gang
    Li, Junmin
    Feng, Jifeng
    Kinkolykh, Anastasiia
    Knapp, Andrea
    Lin, Tongyu
    CHINESE MEDICAL JOURNAL, 2022, 135 (04) : 433 - 440
  • [22] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong Xiaonan
    Song Yuqin
    Shi Yuankai
    Zhang Qingyuan
    Guo Wei
    Wu Gang
    Li Junmin
    Feng Jifeng
    Kinkolykh Anastasiia
    Knapp Andrea
    Lin Tongyu
    中华医学杂志英文版, 2022, 135 (04) : 433 - 440
  • [23] Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
    Tamar Berger
    Tzippy Shochat
    Shlomzion Aumann
    Boaz Nachmias
    Neta Goldschmidt
    Nurit Horesh
    Reut Harel
    Ariel Aviv
    Ella Shmerts
    Uri Abadi
    Shai Shimony
    Pia Raanani
    Anat Gafter‑Gvili
    Ronit Gurion
    Annals of Hematology, 2023, 102 : 2127 - 2136
  • [24] Choosing First-Line Therapy for Follicular Lymphoma (FL): A Decision Analysis
    Olin, Rebecca L.
    Kanetsky, Peter A.
    Ten Have, Thomas
    Nasta, Sunita Dwivedy
    Schuster, Stephen J.
    Andreadis, Charalambos
    BLOOD, 2008, 112 (11) : 250 - 251
  • [25] RADIOTHERAPY PLUS RITUXIMAB AS FIRST-LINE REGIMEN FOR LOCALIZED FOLLICULAR LYMPHOMA
    Cencini, E.
    Puccini, B.
    Rigacci, L.
    Fabbri, A.
    Kovalchuk, S.
    Mannelli, L.
    Benelli, G.
    Carfagno, T.
    Simontacchi, G.
    Bocchia, M.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 108 - 109
  • [26] Determinants of the optimal first-line therapy for follicular lymphoma: A decision analysis
    Olin, Rebecca L.
    Kanetsky, Peter A.
    Ten Have, Thomas R.
    Nasta, Sunita D.
    Schuster, Stephen J.
    Andreadis, Charalambos
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (04) : 255 - 260
  • [27] The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
    Fowler, Nathan H.
    Nastoupil, Loretta
    De Vos, Sven
    Knapp, Mark
    Flinn, Ian W.
    Chen, Robert
    Advani, Ranjana H.
    Bhatia, Sumeet
    Martin, Peter
    Mena, Raul
    Davis, Richard Eric
    Neelapu, Sattva S.
    Eckert, Karl
    Ping, Jerry
    Co, Melannie
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Palomba, M. Lia
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : 650 - 660
  • [28] Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma
    Cencini, Emanuele
    Puccini, Benedetta
    Rigacci, Luigi
    Fabbri, Alberto
    Kovalchuk, Sofia
    Mannelli, Lara
    Benelli, Gemma
    Carfagno, Tommaso
    Simontacchi, Gabriele
    Bocchia, Monica
    Bosi, Alberto
    LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1420 - 1426
  • [29] Prospects in the management of patients with follicular lymphoma beyond first-line therapy
    Qualls, David
    Salles, Gilles
    HAEMATOLOGICA, 2022, 107 (01) : 19 - 34
  • [30] Obinutuzumab Treatment of Follicular Lymphoma
    Nair, Ranjit
    Tabchi, Samer
    Hagemeister, Frederick
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (26): : 2605 - 2605
12345